Skip to content
naulon
Not checkedNot checked for notices yet.

Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia

Huda A Rasheed, Nawar R Hussien, Marwa S Al-Naimi and 2 more

Biomedical and Biotechnology Research Journal · 2020

doi:10.4103/bbrj.bbrj_26_20 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Background: Dyslipidemia (DL) is a blood lipid disorder characterized by high cholesterol, triglyceride and low density lipoprotein with reduction of high density lipoprotein. Crataegus Oxyacantha hawthorn (COH) is used in treatment of hyperlipidemia, hypertension, angina pectoris and arrhythmia as alternative medicine. The aim of the present study was to evaluate the effect of fenofibrate alone or in combination with Crataegus Oxyacantha on lipid profile in patients with mixed dyslipidemia. Methods: A total number of 64 patients with MD on fenofibrate therapy compared to 24 healthy controls were recruited and randomized into three groups: Group A: (control, n = 24) not received any lipid-lowering agents, Group B: (fenofibrate, n = 30) received fenofibrate 200 mg/day for 10 weeks, and Group C: (combination, n = 34) received fenofibrate 200 mg/day plus C. oxycantha for 10 weeks. The estimation of lipid profile and blood pressure changes were done at baseline and following 10 weeks of therapy. Results: Following 10 weeks of C. oxycantha add on fenofibrate therapy, there was a significant reduction on total cholesterol, triglyceride, non-high-density lipoprotein-cholesterol AI, and low-density lipoprotein plasma levels compared with fenofibrate-treated patients (P < 0.05). Blood pressure profile showed more significant reduction in patients with dyslipidemia (DL) treated with C. oxycantha compared with baseline data and with patients with DL treated with fenofibrate alone (P < 0.05). Fenofibrate plus C. oxycantha showed more significant reduction on high-sensitive C-reactive protein serum levels from 5.28 ± 1.61 mg/dL to 2.74 ± 1.99 mg/dL, P < 0.0001. Conclusion: C. oxycantha synergized the effect of fenofibrate therapy in patients with MD through the improvement of lipid profile and attenuation of endothelial inflammation.

Abstract licence: CC BY-NC-SA

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.